226 results on '"Cohen, Joshua M."'
Search Results
2. Gender Considerations in Rhinoplasty
3. State and Institutional Policies on In-State Resident Tuition and Financial Aid for Undocumented Students: Examining Constraints and Opportunities
4. Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies
5. Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
6. Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies
7. Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
8. A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States
9. Facial Expansion: A Blueprint for Coverage
10. Subcutaneous Lateral Temporal Lift
11. Comment on: Gao B, Lu Q, Wan R, Wang Z, Yang Y, Chen Z, Wang Z. “Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials”. Naunyn Schmiedebergs Arch Pharmacol. 2021 Apr;394(4):819–828. Epublished November 2020
12. Osteosarcopenia and Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement.
13. Immunogenicity of biologic therapies for migraine: a review of current evidence
14. Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study
15. Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study
16. Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
17. Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial
18. Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials
19. Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies
20. Wyoming
21. Targeted Nrf2 activation therapy with RTA 408 enhances regenerative capacity of diabetic wounds
22. The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study
23. Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study
24. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study
25. Wyoming
26. Effect of fremanezumab on quality of life and productivity in patients with chronic migraine
27. Effective Treatment of Platysma Bands with Neurotoxin
28. New Mexico
29. Survival after Digit Replantation and Revascularization Is Not Affected by the Use of Interpositional Grafts during Arterial Repair
30. Is the Medial Sural Artery Perforator Flap a New Workhorse Flap? A Systematic Review and Meta-Analysis
31. Physician and patient preferences for dosing options in migraine prevention
32. Clinical characteristics and patient‐reported outcomes of chronic and episodic migraine patients at a US tertiary headache center: A retrospective observational study.
33. Facial Expansion: A Blueprint for Coverage.
34. Advances in Upper Extremity Scleroderma Wound Care
35. Methamphetamine use and adoption of preventive behaviors early in the COVID-19 pandemic among men who have sex with men in Los Angeles, California
36. Fremanezumab as Add‐On Treatment for Patients Treated With Other Migraine Preventive Medicines
37. Burden of migraine in Brazil: A cross‐sectional real‐world study.
38. Headache and Dizziness: How to Differentiate Vestibular Migraine from Other Conditions
39. A Case of Barotrauma-Induced Post-Traumatic Headache With a Cluster Headache Phenotype
40. Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments.
41. Young Adults With Headaches: The Transition From Adolescents to Adults
42. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine
43. Efficacy and quality‐of‐life improvements with fremanezumab treatment in patients with difficult‐to‐treat migraine with associated neurological dysfunction.
44. Epidemiology of cluster headache
45. Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid.
46. Efficacy and Safety of Fremanezumab in Patients with Episodic and Chronic Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications during the Open Label Period of the Phase 3b FOCUS Study
47. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine.
48. Migraine and Vestibular Symptoms—Identifying Clinical Features That Predict “Vestibular Migraine”
49. Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine‐preventive medications in the phase 3b FOCUS study
50. Evidence-Based Medicine in Plastic Surgery: From Then to Now.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.